Neoadjuvant nivolumab and ipilimumab leads to a pathological response in a high proportion of patients with locally advanced dMMR colon cancer

 Results of NICHE-2, "a large phase II study involving patients with locally advanced mismatch repair-deficient (dMMR) colon cancers..." was recently published in the New England Journal of Medicine. As mentioned by the study authors, staging of dMMR colon cancer presents a number of challenges, due to microsatellite instability associated with "false positive enlarged lymph nodes owing to immune infiltration."  

To read more about the NICHE-2 study, click here. 

Source mentioned: 

• Chalabi M, Verschoor YL, Batista Tan P, et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer. N Engl J Med 2024;390:1949-1958.
• Cercek A. Neoadjuvant Treatment of Mismatch Repair–Deficient Colon Cancer — Clinically Meaningful? N Engl J Med 2024;390:2024-2025.